Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

Spinal Cord Injury Treatment by Applying a Composite Scaffold Transplanted with Mesenchymal Stem Cells and Chitosan-Coated Nanostructured Lipid Carriers of Curcumin.

Karami A., Molavi AM., Babaloo H., Farhadian N.

Animal Study on Spinal Cord Injury, Chronic Inflammation, published in ACS Appl Bio Mater (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
ACS Appl Bio Mater (2025)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
40765201
DOI
10.1021/acsabm.5c00636

Abstract (original English)

Background: Spinal cord injury (SCI) is one of the long-term neurological deficits with primary and secondary damages. Various treatment strategies have not been successful in SCI treatment. The aim of this study was to design a platform containing a scaffold, an anti-inflammatory nanostructured drug, and stem cells for SCI treatment. Methods: For this aim, a fibrous composite scaffold of polyurethane/alginate was prepared using the electrospinning method. The hot homogenization method was utilized to encapsulate curcumin as an anti-inflammatory drug in the nanostructured lipid carrier (NLC). NLCs were coated with chitosan polymer (CS) in a core-shell structure for better attachment to the scaffold's surface. The scaffold was covered with CS-coated NLCs and adipose-derived mesenchymal stem cells (ADMSC). The final platform was placed in the female Wistar rat model with spinal cord injury, and the therapeutic and anti-inflammatory effects at the lesion site, as well as behavioral analysis of rats, were investigated. Results: Results confirmed successful formation of the platform with proper attachment of the cells to the scaffold surface and more cell proliferation. Spreading the cells on the scaffold confirmed this scaffold as a good extracellular matrix. The efficacy of this platform in an in vivo environment showed the successful improvement of SCI in rats by increasing the m

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
CurcuminSpinal Cord InjuriesChitosanAnimalsMesenchymal Stem CellsRats, WistarRatsFemaleTissue ScaffoldsNanostructures

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research